Equities research analysts expect that Allergan PLC. (NYSE:AGN) will announce earnings of $4.75 per share for the current fiscal quarter, Zacks reports. Nineteen analysts have provided estimates for Allergan PLC.’s earnings, with estimates ranging from $4.51 to $4.94. Allergan PLC. posted earnings of $3.90 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 21.8%. The firm is scheduled to report its next earnings report on Wednesday, February 14th.
On average, analysts expect that Allergan PLC. will report full-year earnings of $16.23 per share for the current year, with EPS estimates ranging from $15.97 to $16.39. For the next year, analysts anticipate that the firm will post earnings of $16.84 per share, with EPS estimates ranging from $15.00 to $18.38. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Allergan PLC..
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. Allergan PLC.’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business earned $3.32 EPS.
A number of brokerages have recently issued reports on AGN. Morgan Stanley dropped their price target on shares of Allergan PLC. from $228.00 to $200.00 and set an “equal weight” rating on the stock in a report on Thursday. Cantor Fitzgerald dropped their price target on shares of Allergan PLC. to $191.00 and set a “neutral” rating on the stock in a report on Thursday. Wells Fargo & Company reaffirmed an “outperform” rating and set a $245.00 price target (down previously from $258.00) on shares of Allergan PLC. in a report on Thursday. Royal Bank Of Canada dropped their price target on shares of Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Zacks Investment Research raised shares of Allergan PLC. from a “sell” rating to a “hold” rating in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $246.73.
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after purchasing an additional 482,220 shares in the last quarter. Northern Trust Corp raised its position in shares of Allergan PLC. by 8.8% during the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock valued at $1,092,189,000 after buying an additional 364,722 shares during the last quarter. Veritas Asset Management LLP bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $761,339,000. Edgewood Management LLC raised its position in shares of Allergan PLC. by 7.0% during the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its position in shares of Allergan PLC. by 3.8% during the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares during the last quarter. 82.14% of the stock is currently owned by institutional investors and hedge funds.
Shares of Allergan PLC. (NYSE AGN) opened at $174.92 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The firm has a market cap of $58,175.43, a PE ratio of 11.34, a price-to-earnings-growth ratio of 0.93 and a beta of 1.13. Allergan PLC. has a 12 month low of $169.64 and a 12 month high of $256.80.
Allergan PLC. declared that its Board of Directors has authorized a stock repurchase plan on Monday, September 25th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.60%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is currently -12.44%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.